logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Aromatase Inhibitor class drugs

    FiltersReset Filters
    9 results

    • anastrozole

      (Anastrozole Tablets)
      Avet Pharmaceuticals Inc
      Usage: Anastrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of hormone receptor-positive or unknown locally advanced or metastatic breast cancer, and second-line treatment for advanced breast cancer in patients with disease progression after tamoxifen therapy.

    • anastrozole

      (Anastrozole)
      Chartwell RX, LLC
      Usage: Anastrozole is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, as well as for first-line treatment of hormone receptor-positive or unknown locally advanced/metastatic breast cancer, and as second-line treatment for advanced breast cancer following tamoxifen therapy.

    • anastrozole

      (Anastrozole Tablets)
      Yiling Pharmaceutical, Inc.
      Usage: Anastrozole is indicated for postmenopausal women with hormone receptor-positive early breast cancer as adjuvant treatment, as well as for first-line treatment of hormone receptor-positive or unknown locally advanced or metastatic breast cancer. It is also used as second-line therapy after tamoxifen failure in advanced cases.

    • arimidex

      (Anastrozole)
      ANI Pharmaceuticals, Inc.
      Usage: ARIMIDEX is indicated for adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for first-line and second-line treatment of hormone receptor-positive or unknown locally advanced and metastatic breast cancer, particularly after disease progression on tamoxifen therapy.

    • aromasin

      (exemestane)
      Pharmacia & Upjohn Company LLC
      Usage: AROMASIN is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after two to three years of tamoxifen therapy, and for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen.

    • exemestane

      (Exemestane)
      Florida Pharmaceutical Products, LLC
      Usage: Exemestane is indicated for postmenopausal women with estrogen-receptor positive early breast cancer as adjuvant treatment after 2-3 years of tamoxifen, and for advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

    • exemestane

      (Exemestane)
      Greenstone LLC
      Usage: EXEMESTANE is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after 2-3 years of tamoxifen therapy, and for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed after tamoxifen.

    • letrozole

      (Letrozole)
      Chartwell RX, LLC
      Usage: Letrozole Tablets are indicated for the adjuvant and extended adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, as well as for first and second-line treatment of locally advanced or metastatic breast cancer in postmenopausal women.

    • letrozole

      (Letrozole Tablets)
      Yiling Pharmaceutical, Inc.
      Usage: Letrozole is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for extended adjuvant therapy following tamoxifen. It is also used as a first and second-line treatment for advanced, locally advanced, or metastatic breast cancer in postmenopausal women.